Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Opy Acquisition Corp. IOHAA · Entity 133726 | Director | October 26, 2021 | October 27, 2021 |
| Parabilis Medicines, Inc.PBLS · Entity 3933 | Director | June 09, 2026 | June 11, 2026 |
| Revolution Medicines, Inc.RVMD · Entity 606 | Director | October 08, 2024 | October 10, 2024 |
| Tango Therapeutics, Inc.TNGX · Entity 1497 | Director · Director, Executive Chair | February 02, 2026 | February 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Opy Acquisition Corp. I
Report date October 26, 2021 · Filed October 27, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2021-10-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Parabilis Medicines, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2036-06-08 | Direct | 20,215 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 20,215 · Balance 20,215 F1: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Revolution Medicines, Inc.
Report date October 08, 2024 · Filed October 10, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,065 |
Reported balance
After 2024-10-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-10-08 · Sale · Disposed 5,200 · Balance 13,065 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 29, 2024. F2: The transaction was executed in multiple trades in prices ranging from $48.00 to $48.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: Includes 4,248 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 29, 2024.
F2: The transaction was executed in multiple trades in prices ranging from $48.00 to $48.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: Includes 4,248 restricted stock units.
Tango Therapeutics, Inc.
Report date February 02, 2026 · Filed February 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,629,254 |
Ending reported balance
After 2026-02-03 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-02-02 · Grant · Acquired 37,522 · Balance 1,659,773 F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in full on February 1, 2027, subject to the Reporting Person's continuous service with the Issuer as of such vesting date. Row 2 · 2026-02-03 · Sale · Disposed 30,186 · Balance 1,629,587 F2: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $11.88 to $12.875 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 3 · 2026-02-03 · Sale · Disposed 333 · Balance 1,629,254 F2: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F4: Represents the weighted average sales price per share. The shares sold at prices ranging from $12.88 to $12.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.94 · Expires 2036-02-02 | Direct | 222,132 |
Reported balance
After 2026-02-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-02 · Grant · Acquired 222,132 · Balance 222,132 F5: This option shall vest and become exercisable in 12 equal monthly installments following January 1, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in full on February 1, 2027, subject to the Reporting Person's continuous service with the Issuer as of such vesting date.
F2: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $11.88 to $12.875 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F4: Represents the weighted average sales price per share. The shares sold at prices ranging from $12.88 to $12.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F5: This option shall vest and become exercisable in 12 equal monthly installments following January 1, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2020 Filed Oct 6, 2020 00:17 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 804 | $36.02 | $28,959.52 |
DisclosureSEC source: 0001567619-20-017604 · doc1.xml · nonDerivative · entry 4 Weber Barbara · CIK 0001800670 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,808 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $36.00 to $36.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 1,808 Restricted Stock Units. Read SEC document |
| October 02, 2020 Filed Oct 6, 2020 00:17 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 804 | $1.12 | $900.48 |
DisclosureSEC source: 0001567619-20-017604 · doc1.xml · nonDerivative · entry 3 Weber Barbara · CIK 0001800670 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 1,808 Restricted Stock Units. Read SEC document |
| October 01, 2020 Filed Oct 6, 2020 00:17 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001567619-20-017604 · doc1.xml · derivative · entry 7 Weber Barbara · CIK 0001800670 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,825 Underlying: Common Stock · 2,000 shares Expires 2028-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: This option is early exercisable. Twenty-five percent of the total shares subject to the option vested on the first anniversary measured from April 20, 2018 (the "Vesting Commencement Date") and one sixteenth (1/16th) of the shares subject to the option will vest quarterly thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| October 01, 2020 Filed Oct 6, 2020 00:17 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,000 | $34.76 | $69,521.00 |
DisclosureSEC source: 0001567619-20-017604 · doc1.xml · nonDerivative · entry 2 Weber Barbara · CIK 0001800670 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,808 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $34.26 to $35.21, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 1,808 Restricted Stock Units. Read SEC document |
| October 01, 2020 Filed Oct 6, 2020 00:17 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 2,000 | $1.12 | $2,240.00 |
DisclosureSEC source: 0001567619-20-017604 · doc1.xml · nonDerivative · entry 1 Weber Barbara · CIK 0001800670 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 1,808 Restricted Stock Units. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 22:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 333 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001567619-20-015578 · doc1.xml · derivative · entry 6 Weber Barbara · CIK 0001800670 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,825 Underlying: Common Stock · 333 shares Expires 2028-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: This option is early exercisable. Twenty-five percent of the total shares subject to the option vested on the first anniversary measured from April 20, 2018 (the "Vesting Commencement Date") and one sixteenth (1/16th) of the shares subject to the option will vest quarterly thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 22:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 333 | $28.00 | $9,324.00 |
DisclosureSEC source: 0001567619-20-015578 · doc1.xml · nonDerivative · entry 4 Weber Barbara · CIK 0001800670 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,808 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 1,808 Restricted Stock Units. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 22:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 333 | $1.12 | $372.96 |
DisclosureSEC source: 0001567619-20-015578 · doc1.xml · nonDerivative · entry 3 Weber Barbara · CIK 0001800670 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 1,808 Restricted Stock Units. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 22:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,667 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001567619-20-015578 · doc1.xml · derivative · entry 5 Weber Barbara · CIK 0001800670 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,158 Underlying: Common Stock · 1,667 shares Expires 2028-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: This option is early exercisable. Twenty-five percent of the total shares subject to the option vested on the first anniversary measured from April 20, 2018 (the "Vesting Commencement Date") and one sixteenth (1/16th) of the shares subject to the option will vest quarterly thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 22:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,667 | $28.00 | $46,676.00 |
DisclosureSEC source: 0001567619-20-015578 · doc1.xml · nonDerivative · entry 2 Weber Barbara · CIK 0001800670 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,808 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 1,808 Restricted Stock Units. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 22:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 1,667 | $1.12 | $1,867.04 |
DisclosureSEC source: 0001567619-20-015578 · doc1.xml · nonDerivative · entry 1 Weber Barbara · CIK 0001800670 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 1,808 Restricted Stock Units. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 19:35 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 6,329 | $0.00 Strike: $36.57 | $0.00 |
DisclosureSEC source: 0001567619-20-012444 · doc1.xml · derivative · entry 2 Weber Barbara · CIK 0001800670 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,329 Underlying: Common Stock · 6,329 shares Expires 2030-06-16 F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 17, 2020 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 19:35 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 1,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-012444 · doc1.xml · nonDerivative · entry 1 Weber Barbara · CIK 0001800670 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,808 F1 · balance_after: Includes 1,808 Restricted Stock Units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.